Recent and select publications
Singh AK, Lewis CD, Boas CAWV, Diebolder P, Jethva PN, Rhee A, Song JH, Goo YA, Li S, Nickels ML, Liu Y, Rogers BE, Kapoor V, Hallahan DE: Development of a [89Zr]Zr-labeled human antibody using a novel phage-displayed human scFv library. Clin Cancer Res 30:1293, 2024
Benabdallah N, Lu P, Abou DS, Zhang H, Ulmert D, Hobbs RF, Gay HA, Simons BW, Saeed MA, Rogers BE, Jha AK, Tai YC, Malone CD, Ippolito JE, Michalski J, Jennings JW, Baumann BC, Pachynski RK, Thorek DLJ: Beyond average: a-particle distribution and dose-heterogeneity in bone metastatic prostate cancer. J Nucl Med 65:245, 2024.
Sreekumar S, Zhou D, Mpoy C, Schenk E, Scott J, Arbeit JM, Xu J, Rogers BE: Preclinical efficacy of a PARP-1 targeted Auger-emitting radionuclide in prostate cancer. Int J Mol Sci 24:3083, 2023.
Kang CS, Zhang S, Wang H, Liu Y, Ren S, Chen Y, Li J, Bandara N, Rogachev AY, Rogers BE, Chong HS: Novel chelating agents for zirconium-89-positron emission tomography (PET) imaging: Synthesis, DFT calculation, radiolabeling, and in vitro and in vivo complex stability. ACS Omega 7:37229-37236, 2022.
Huynh TT, Wang Y, Terpstra K, Cho HJ, Mirica LM, Rogers BE: 68Ga-labeled benzothiazole derivatives for imaging Ab plaques in cerebral amyloid angiopathy. ACS Omega 7:20339-20346, 2022.
Huynh TT, van Dam EM, Sreekumar S, Mpoy C, Blyth BJ, Muntz F, Harris MJ, Rogers BE: Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer. Pharmaceuticals 15:728, 2022.
Huynh TT, Sreekumar S, Mpoy C, Rogers BE: A comparison of 64Cu-labeled bi- terminally PEGylated A20FMDV2 peptides targeting integrin avb6. Oncotarget 13:360-372, 2022.
Diebolder P, Mpoy C, Scott J, Huynh TT, Fields R, Spitzer D, Bandara N, Rogers BE: Preclinical evaluation of an engineered scFv-Fc targeting human CD44. J Nucl Med 62:137-143, 2021.
De Silva RA, Jain S, Lears KA, Chong HS, Kang CS, Sun X, Rogers BE: Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development. Nucl Med Biol 39:1099-1104, 2012. PMCID: PMC3470735.
Kang CS, Wu N, Chen Y, Bandara N, Liu D, Lewis MR, Rogers BE, Chong HS: Transferrin conjugates of triazacyclononane-based bifunctional NE3TA chelates for PET imaging: Synthesis, Cu-64 radiolabeling, and in vitro and in vivo evaluation. J Inorg Biochem 154:60-66, 2016. PMCID: PMC4679499.
Kapoor V, Dadey DY, Nguyen K, Wildman SA, Hoye K, Khudanyan A, Bandara N, Rogers BE, Thotala D, Hallahan DE: Tumor specific binding of radiolabeled PEGylated GIRLRG peptide; a novel agent for targeting cancers. J Nucl Med Epub, 2016.
Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE: In vitro and in vivo evaluation of 64Cu-Labeled SarAr-Bombesin Analogs in Gastrin-Releasing Peptide Receptor-Expressing Prostate Cancer. J Nucl Med 52:470-477, 2011. PMCID: PMC3088991.
Lears KA, Parry JJ, Andrews R, Nguyen K, Wadas TJ, Rogers BE: Adenoviral-mediated imaging of gene transfer using a somatostatin receptor-cytosine deaminase fusion protein. Cancer Gene Ther 22:215-221, 2015. PMCID: PMC4409539.
Liu L, Rogers BE, Aladyshkina N, Cheng B, Lokitz SJ, Curiel DT, Mathis JM: Construction and radiolabeling of adenovirus variants that incorporate human metallothionein into protein IX for analysis of biodistribution. Mol Imaging 13:1-12, 2014. PMCID: None.
Richter S, Wuest M, Bergman CN, Way JD, Krieger S, Rogers BE, Wuest F: Rerouting the metabolic pathway of 18F-labeled peptides: the influence of prosthetic groups. Bioconjug Chem 26:201-212, 2015. PMCID: None.
Richter S, Wuest M, Bergman CN, Krieger S, Rogers BE, Wuest F: Metabolically stabilized 68Ga-NOTA-Bombesin for PET imaging of prostate cancer and influence of protease inhibitor phosphoramidon. Mol Pharm 13:1347-1357, 2016. PMCID: None.
Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ: MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem 14:756-763, 2003. PMCID: None.
Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ: Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region. Cancer Biother Radiopharm 20:502-513, 2005. PMCID: None.
Sin, I.; Kang, C.; Bandara, N.; Sun, X; Zhong, Y.; Rogers, B. E; Chong, H.S., “Novel Hexadentate and Pentadentate Chelators for 64Cu-based Targeted PET Imaging”, Med. Chem. 2014, 22, 2553-2562.